Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a research note released on Wednesday morning,Zacks reports. The firm issued a strong-buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at $1.60 EPS, Q3 2027 earnings at $3.13 EPS and Q4 2027 earnings at $4.16 EPS.

Several other analysts also recently weighed in on MDGL. Wells Fargo & Company started coverage on shares of Madrigal Pharmaceuticals in a report on Monday, July 27th. They issued an “overweight” rating and a $685.00 target price on the stock. Wolfe Research raised shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target for the company in a report on Tuesday, August 4th. Citigroup raised their price objective on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity Group lifted their price objective on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a “buy” rating in a report on Wednesday. Finally, The Goldman Sachs Group assumed coverage on Madrigal Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $704.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $706.87.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $400.43 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94. The firm has a market cap of $9.25 billion, a price-to-earnings ratio of -66.96 and a beta of -0.98. The firm’s fifty day moving average price is $492.40 and its 200 day moving average price is $498.45. Madrigal Pharmaceuticals has a 1-year low of $353.54 and a 1-year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.93%. During the same quarter in the prior year, the firm earned ($5.08) EPS. On average, sell-side analysts expect that Madrigal Pharmaceuticals will post -7.03 EPS for the current year.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, CEO William Sibold sold 5,221 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the transaction, the chief executive officer directly owned 197,746 shares of the company’s stock, valued at $107,255,452.94. This represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon Kelley sold 664 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the transaction, the general counsel owned 11,474 shares of the company’s stock, valued at $5,908,765.78. This represents a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 12,247 shares of company stock worth $6,581,182 over the last 90 days. Insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Concurrent Investment Advisors LLC lifted its stake in Madrigal Pharmaceuticals by 2.0% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,034 shares of the biopharmaceutical company’s stock valued at $555,000 after buying an additional 20 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Madrigal Pharmaceuticals by 2.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 1,664 shares of the biopharmaceutical company’s stock valued at $839,000 after buying an additional 43 shares during the last quarter. ProShare Advisors LLC increased its position in Madrigal Pharmaceuticals by 5.5% during the third quarter. ProShare Advisors LLC now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after buying an additional 44 shares in the last quarter. GAMMA Investing LLC increased its position in Madrigal Pharmaceuticals by 35.4% during the second quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 45 shares in the last quarter. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Madrigal Pharmaceuticals by 9.8% in the third quarter. Oppenheimer & Co. Inc. now owns 540 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q3 results topped expectations: Madrigal reported EPS of $1.83, versus the consensus estimate of a $1.09 loss, and revenue of $431.27 million, above expectations of $404.17 million. Rezdiffra sales reportedly surpassed $1 billion, helping the company swing to a quarterly profit. Article: Madrigal Swings To Q3 Profit As Rezdiffra Sales Jump 50%
• Positive Sentiment: Analysts remain constructive: HC Wainwright initiated coverage with a Strong Buy rating and projected improving 2027 earnings, including positive EPS in the second half of the year. Canaccord raised its target to $633, while Truist raised its target to $743 and reaffirmed Buy. HC Wainwright recommendations
• Neutral Sentiment: Clinical development continues: Madrigal anticipates a late-2027 MAESTRO-NASH OUTCOMES readout and is planning a study enrolling more than 2,000 patients. These are longer-term developments rather than immediate catalysts. Article: Madrigal anticipates late 2027 readout and study
• Negative Sentiment: Legal overhang: Two law firms announced investigations into potential securities-law violations involving Madrigal and its management. The notices do not establish wrongdoing, but may add uncertainty for investors. Article: Madrigal securities investigation
• Negative Sentiment: Profitability concerns remain: Despite the quarterly profit, coverage has pointed to uncertainty around near-term profitability, a concern that may temper the positive earnings reaction. Article: MDGL stock and near-term profitability concerns

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.